An Open-Label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507633-21-01

Acronym

MN45053

Enrollment

136

Registered

2024-11-22

Start date

2024-12-09

Completion date

Unknown

Last updated

2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

1. Change from baseline to end of study in Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a), 2. Number of eligible participants who have received access to ocrelizumab in the study (time frame: up to 5 years)

Detailed description

1. The incidence, nature, severity and outcome of serious adverse events, adverse events leading to discontinuation, and adverse events of special interest

Interventions

DRUGOcrevus 300 mg concentrate for solution for infusion

DRUGOcrevus 920 mg solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Change from baseline to end of study in Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a), 2. Number of eligible participants who have received access to ocrelizumab in the study (time frame: up to 5 years)	—

Secondary

Measure	Time frame
1. The incidence, nature, severity and outcome of serious adverse events, adverse events leading to discontinuation, and adverse events of special interest	—

Countries

Bulgaria, France, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026